Skip to content
Study details
Enrolling now

Adenovirus-Specific Cytotoxic T-Lymphocytes for Refractory Adenovirus Infection

New York Medical College
NCT IDNCT03266627ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

20

Study length

about 9.2 years

Ages

0.0833333333333333–79

Locations

10 sites in CA, CO, IN +5

What this study is about

This trial is testing a treatment with adenovirus-specific cytotoxic T cells in children, adolescents, and young adults who have a severe adenovirus infection that hasn't responded to other treatments. The treatment will be given after a stem cell transplant for primary immune deficiency disorders or solid organ transplants.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take cytotoxic t-lymphocytes

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]